Ann: Change in substantial holding from HHL, page-29

Oh dear. So UBS are now going to get clients funds into SRX above $36 in the run-up to trial result based on a review of already published journey studies. My god. I hope everything goes as planned. Even Roger Montgomery's crowd are even throwing their 'do not buy above intrinsic value' mantra out the window and have basically said the upside on 'PUNTING' on a good trial result with SRX may outweigh the risk. This seems to be irrational speculative undertakings at and above these price levels with significant capital losses to be realised if the trial results:
A: Do not achieve primary endpoint (failure)
B: Achieve primary endpoint but result is statistically weak

Don't forget SRX own specialists have admitted that even a highly positive result may not be enough to elevate SIRSpheres to top line treatment because the vast majority of key opinion leaders and oncologists rely on overall survival data from trials (SRX endpoint is progression free survival).

IMO the deck is stacked against SIRSpheres achieving first line treatment anytime soon. Good luck all though. I hope I am wrong.